tepotinib

MET inhibitor

Also Known As:

3-(1-(3-(5-((1-Methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)benzyl)-6-oxo-1,6-dihydro-3-pyridazinyl)benzonitrile; benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo-3-pyridazinyl)-; tepmetko

Networked: 74 relevant articles (5 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds

Experts

1.	Bruns, Rolf: 6 articles (01/2022 - 01/2020)
2.	Johne, Andreas: 6 articles (01/2022 - 01/2020)
3.	Berghoff, Karin: 5 articles (01/2022 - 01/2021)
4.	Straub, Josef: 5 articles (08/2021 - 01/2020)
5.	Friese-Hamim, Manja: 4 articles (01/2022 - 01/2017)
6.	Girard, Pascal: 4 articles (01/2022 - 01/2020)
7.	Stroh, Christopher: 4 articles (01/2022 - 01/2020)
8.	Xiong, Wenyuan: 4 articles (01/2022 - 01/2020)
9.	Chen, Yuh-Min: 3 articles (01/2022 - 01/2020)
10.	Paik, Paul K: 3 articles (01/2022 - 01/2020)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2023 - "The VISION trial showed durable activity of tepotinib in MET exon 14 (METex14) skipping non-small cell lung cancer. " 11/21/2023 - "Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B." 11/01/2023 - "Tepotinib is a highly selective, potent type Ib MET inhibitor and approved for treatment of non-small cell lung cancer harboring METex14 skipping alterations. " 01/01/2023 - "Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial." 01/01/2023 - "Tepotinib is currently approved for the treatment of adult patients with advanced or metastatic non-small cell lung cancer harboring MET exon 14 skipping alterations. "
2.	Brain Neoplasms (Brain Tumor) 01/01/2022 - "Tepotinib showed meaningful activity across subgroups by age, prior therapies, and brain metastases, with a manageable safety profile and few treatment discontinuations. " 01/01/2022 - "Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases." 12/01/2020 - "Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report." 01/01/2022 - "Of 20 screened subcutaneous patient-derived xenograft (PDX) models from lung cancer brain metastases (n = 1), two NSCLC brain metastases models (LU5349 and LU5406) were sensitive to the suboptimal dose of tepotinib of 30 mg/kg/qd (tumor volume change [%TV]: -12% and -88%, respectively). " 01/01/2022 - "MET inhibitors, which exhibited a satisfactory safety profile in the current study, may become a new standard of care for addressing MET dysregulation in patients with advanced or metastatic NSCLC, and even in those with brain metastases, particularly tepotinib, savolitinib and capmatinib. "
3.	Edema (Dropsy) 01/01/2023 - "The main adverse event of tepotinib treatment is edema. " 01/01/2022 - "Edema is the most frequently reported adverse event and the most frequent cause of tepotinib dose reductions and interruptions; however, the effect plateaued at low exposures. " 01/01/2020 - "Adverse events of grade 3 or higher that were considered by investigators to be related to tepotinib therapy were reported in 28% of the patients, including peripheral edema in 7%. " 12/01/2021 - "Peripheral edema has been identified as one of the most common adverse events in capmatinib and tepotinib; however, there is no unified management for this adverse event. " 12/01/2021 - "Herein, we present a case of intolerable peripheral edema caused by tepotinib, in which MET inhibitor could be continued by switching to capmatinib. "
4.	Neoplasm Metastasis (Metastasis) 01/01/2021 - "These demonstrate tepotinib could achieve a high rate of central nervous system transition and could be effective against leptomeningeal metastasis." 01/01/2021 - "Moreover, information about the efficacy of tepotinib in patients with leptomeningeal metastasis is limited. " 01/01/2023 - "Tepotinib penetrates the blood-brain barrier and demonstrates strong antitumor activity in subcutaneous and orthotopic brain metastasis models, in-line with clinical activity observed in patients. " 03/01/2021 - "We here report a case of a patient with NSCLC with MET exon 14 skipping mutation and poor performance status salvaged by marked leptomeningeal metastases response to tepotinib. " 01/01/2021 - "Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation."
5.	Pneumonia (Pneumonitis) 10/05/2022 - "Tepotinib may be a safe option when medical professionals consider switching MET inhibitors after patients experience pneumonitis." 10/05/2022 - "Here, we present a case of a patient with NSCLC harboring a METex14 who was treated with a standard dose of tepotinib after advanced capmatinib-induced pneumonitis and did not present pneumonitis relapse. " 10/05/2022 - "However, drug-induced pneumonitis is an uncommon but threatening adverse effect found in patients treated with both capmatinib and tepotinib. " 10/05/2022 - "Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report."

Related Drugs and Biologics

1.	capmatinib
2.	Diuretics
3.	Sorafenib (BAY 43-9006)
4.	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazine
5.	osimertinib
6.	Tyrosine Kinase Inhibitors
7.	Crizotinib
8.	Proto-Oncogene Proteins c-met
9.	Gefitinib (Iressa)
10.	Catenins

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Tapering
3.	Physical Therapy Modalities (Physical Therapy Technique)
4.	Drug Therapy (Chemotherapy)
5.	Precision Medicine